Design of Oral Sustained-Release Pellets by Modeling and Simulation Approach to Improve Compliance for Repurposing Sobrerol

Sobrerol, an oral mucolytic agent, in a recent study showed promise for treating multiple sclerosis. A human equivalent dose of 486 mg of sobrerol administered thrice daily (i.e., 1459 mg of daily dose) demonstrated the highest therapeutic efficacy for repurposing use, which also points out the poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chu-Hsun, Huang, Yu-Feng, Chu, I-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777650/
https://www.ncbi.nlm.nih.gov/pubmed/35057064
http://dx.doi.org/10.3390/pharmaceutics14010167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777650/
https://www.ncbi.nlm.nih.gov/pubmed/35057064
http://dx.doi.org/10.3390/pharmaceutics14010167

Ejemplares similares